longbridgelongbridge
  • 平台特色
    特色
    投資產品私人財富管理交易工具行情服務分析工具資訊服務開發者平台
    賬戶類型
    個人客戶機構客戶
  • Café
longbridge
© 2026 Longbridge|服務條款隱私政策

表現優異的製藥股票仍具備上漲潛力

Schaeffers
2026年9月3日 晚上06:30
LongbridgeAI我是 LongbridgeAI,我可以總結文章信息。

梯瓦製藥 (TEVA) 的交易價格接近 $36.41,較 8 月份的高點 $38.36 回落。儘管看跌期權與看漲期權的比率偏向悲觀,但由於隱含波動率較低,該股票產生了歷史性的牛市信號。歷史數據顯示,當 TEVA 的波動率指數處於底部 20 百分位且接近 52 周高點時,80% 的情況下會出現上漲,平均漲幅為 5.5%。這表明有可能向之前的高點回升

Teva Pharmaceuticals Industries (NYSE:TEVA) is moving 2.9% lower to trade at $36.41, pulling back from its Aug. 27, nearly nine-year high of $38.36. The $36 level looks to have moved in as a floor of support, a former level of resistance for the shares since late January. More gains could be on the table, however, with a fresh bull signal now flashing for the drug maker.

TEVA's long-term outperformance comes amid historically low implied volatility (IV). Specifically, the equity's current SVI of 29% stands in the low 5th percentile of its annual range.

According to data from Schaeffer’s Senior Quantitative Analyst Rocky White, there have been five instances in the past five years when the equity traded within 2% of its 52-week high, while its Schaeffer’s Volatility Index (SVI) ranked in the 20th percentile of its annual range or lower.

TEVA was higher one month later 80% of the time after those signals, averaging a 5.5% gain. From its current perch, a shift of this amount would put the equity back above $38 -- within a chip-shot of its August peak.

Options traders are still not convinced. This is per the equity's 10-day put/call volume ratio at the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), which sits higher than 96% of readings from the past year. Should this bearish sentiment begin to unwind, it could trigger more tailwinds for the shares.

登錄即免費解鎖922字全文

因資訊版權原因,登錄長橋賬戶後方可瀏覽相關內容
感謝您對正版資訊的理解與支持

梯瓦制藥

梯瓦制藥

TEVA.US

開市價

--

最高價

--

最低價

--

昨收

--

市盈率TTM

--

總市值

--

LongbridgeAI